Head to Head Analysis: Palvella Therapeutics (PVLA) versus Its Competitors

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Palvella Therapeutics to similar companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Institutional and Insider Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Palvella Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of 3.66, meaning that their average share price is 266% more volatile than the S&P 500.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Earnings and Valuation

This table compares Palvella Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.60
Palvella Therapeutics Competitors	$9.55 billion	$137.66 million	-7.35

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Palvella Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8156	21815	49621	1310	2.54

Palvella Therapeutics currently has a consensus price target of $40.33, indicating a potential upside of 108.87%. As a group, “Pharmaceutical preparations” companies have a potential upside of 244.25%. Given Palvella Therapeutics’ competitors higher possible upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Summary

Palvella Therapeutics competitors beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.